Johnson & Johnson (JNJ)vsStandard Biotools Inc (LAB)
JNJ
Johnson & Johnson
$227.35
+1.10%
HEALTHCARE · Cap: $547.28B
LAB
Standard Biotools Inc
$0.93
+4.69%
HEALTHCARE · Cap: $350.48M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 112827% more annual revenue ($96.36B vs $85.33M). JNJ leads profitability with a 21.8% profit margin vs -87.8%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
LAB
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$227.35
$67.22 premium
Intrinsic value data unavailable for LAB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -13.1% — below average capital efficiency
Revenue declined 4.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : LAB
The strongest argument for LAB centers on Price/Book.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : LAB
The primary concerns for LAB are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while LAB is a turnaround play — different risk/reward profiles.
LAB carries more volatility with a beta of 1.42 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 31/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Standard Biotools Inc
HEALTHCARE · MEDICAL DEVICES · USA
Standard Biotools Inc. (LAB) is a pioneering biotechnology company dedicated to enhancing genomic analysis and biological research through cutting-edge tools and technologies. The firm specializes in developing high-performance products that cater specifically to laboratories engaged in genomics and proteomics, thereby significantly improving research precision and operational efficiency. By employing proprietary platforms, Standard Biotools enables researchers to expedite discoveries and elevate the standard of their scientific endeavors. Positioned strategically within the rapidly evolving biotechnology sector, LAB is well-equipped to address the growing need for advanced analytical solutions that are essential to the life sciences industry.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?